A new Center of Excellence for Cancer Immunology and Immunotherapy (CECII) within the Rogel Cancer Center will widen U-M’s scope of cancer immunological clinical research, positioning the institution as a global leader in this hot area of cancer research.
An international consortium of labs tested nine different methods for RNA sequencing to understand and standardize the best methods for sequencing small RNAs. The goal was to create a process that could be reproduced from one lab to the next to the next.
The Association of American Cancer Institutes has established the Champion for Cures Award to recognize individuals who demonstrate significant leadership in supporting efforts to cure cancer and in inspiring others to do the same. The inaugural award will be presented to Richard and Susan Rogel, in recognition of their generous gift to the University of Michigan Rogel Cancer Center, which was renamed in their honor.
Max S. Wicha, a physician-scientist recognized internationally as a leader in cancer stem cell research and immuno-oncology, has been selected as the 2019 Henry Russel Lecturer, considered the University of Michigan’s highest honor for senior faculty members.
U.S. News & World Report ranked C.S. Mott Children’s Hospital No. 1 in Michigan and 24th in the nation for pediatric cancer care in its 2018 rankings of best children’s hospitals.
Many cancer patients use alternative medicine, including supplements, massage therapy, yoga, and acupuncture, while undergoing conventional cancer care. Such therapies are usually acceptable, but patients must discuss such therapies with their oncologist, because interactions may occur.
Researchers at the U-M Rogel Cancer Center have discovered the process that allows immune suppressor cells to develop, suggesting a potential new way to bolster immunotherapy treatment.
The University of Michigan Rogel Cancer Center has partnered with 69 other National Cancer Institute-designated cancer centers to issue a statement urging for increased HPV vaccination and screening to eliminate HPV-related cancers, starting with cervical cancer.
A new study shows how to personalize the lung cancer screening decision for every patient. The results could help doctors fine-tune their advice to patients so that it’s based not only on a patient’s individual lung cancer risk and the potential benefits and harms of screening, but also the patient’s attitude about looking for problems and dealing with the consequences.
Media contact: Jessica Webster-Sendra, 734-764-2220 | Patients may contact Cancer AnswerLine, 800-865-1125